Biofrontera (BFRI) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

BFRI · Stock Price

USD 1.14+0.44 (+64.03%)

Market Cap: $13.7M

Historical price data

Market Cap: $13.7MPipeline: 8 drugs (4 Phase 3)Founded: 2015HQ: Woburn, United States

Sector Ranking#117 in Drug Delivery & Formulation #334 in Small Molecule Drugs

Overview

Biofrontera Inc. is a commercial-stage biopharma company with a mission to become a leading U.S. specialty dermatology firm by providing innovative, high-quality treatment options. Its core achievements include the successful U.S. commercialization of two FDA-approved products, Ameluz® and Xepi®, and the development of a proprietary nanoemulsion technology platform. The company's strategy is to deepen its expertise in photodynamic therapy, expand its portfolio through label extensions and new indications for its core assets, and build a consultative commercial model to serve dermatology healthcare providers.

Dermatology

Technology Platform

Proprietary nanoemulsion technology designed to improve drug stability and enhance skin penetration for topical formulations, forming the core of its photodynamic therapy system.

Pipeline

8

8 drugs in pipeline4 in Phase 3

Drug	Indication	Stage
Ameluz 10% Topical Gel	Actinic Keratoses	Approved
BF-200 ALA + methyl-aminolevulinate	Basal Cell Carcinoma (BCC)	Phase 3
Vehicle + BF-200 ALA	Actinic Keratosis	Phase 3
BF-200 ALA gel + Placebo to BF-200 ALA gel	Actinic Keratosis	Phase 3
BF-200 ALA + MAL Cream + Vehicle	Actinic Keratosis	Phase 3

Opportunities

Label expansion of Ameluz® into large dermatology markets like superficial basal cell carcinoma and acne represents a significant growth opportunity.

The company's focused, consultative commercial model could carve out a sustainable niche in the specialty dermatology community.

Risk Factors

The company faces severe financial risk as a micro-cap entity with likely limited cash reserves, coupled with commercial execution risk against larger competitors.

Pipeline progress is critical, as clinical failure in key Phase III trials would severely limit future prospects.

Competitive Landscape

Biofrontera competes in crowded markets: Ameluz® faces competition from other PDT regimens and numerous topical/widespread AK treatments, while Xepi® competes with generic and branded topical antibiotics. Its small size is a disadvantage against large dermatology-focused pharma companies.